Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study

Cynthia S. Bonhof*, Floortje Mols, M. Caroline Vos, Johanna M. A. Pijnenborg, Dorry Boll, Gerard Vreugdenhil, Nicole P. M. Ezendam, Lonneke V. van de Poll-Franse

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Web of Science)

Abstract

Objective. Chemotherapy-induced peripheral neuropathy (CIPN) presents itself as sensory peripheral neuropathy (SPN) or motor peripheral neuropathy (MPN). Our aim was to examine the course of SPN and MPN, and their impact on health-related quality of life (HRQoL) among ovarian cancer patients. Methods. All newly diagnosed ovarian cancer patients from twelve hospitals in the South of the Netherlands were eligible for participation. Patients (N = 174) completed questions on CIPN (EORTC QLQ-OV28) and HRQoL (EORTCQLQ-C30) after initial treatment and at 6, 12, and 24 months (response rates were 70%, 71%, 58%, and 43% respectively). Results. Generalized linear mixed models showed that among chemotherapy-treated patients (N = 98), SPN levels were stable over time. For MPN, symptoms significantly improved at 12 months. At 2 years, 13% still reported high SPN. Also, 11% still reported high MPN. Regarding HRQoL, patients with high SPN reported a worse physical, role, emotional, social, and cognitive functioning compared to those with low SPN. Moreover, those who changed from low to high SPN over time worsened on physical functioning. For MPN, a worse global quality of life and a worse functioning was reported among patients with high MPN. Also, those who changed from low to high MPN over time worsened on global quality of life and on physical, role, social, and cognitive functioning. Conclusions. Among chemotherapy-treated ovarian cancer patients, SPN levels were stable over time. In contrast, MPN symptoms significantly improved at 12 months. These symptoms seriously impacted HRQoL. Future studies should examine the impact of different treatment decisions and alterations on CIPN, so recommendations can be made to reduce CIPN (prevalence). (C) 2018 Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)455-463
Number of pages9
JournalGynecologic Oncology
Volume149
Issue number3
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • SURVIVORSHIP CARE PLAN
  • EVERY 3 WEEKS
  • REPORTED OUTCOMES
  • 1ST-LINE CHEMOTHERAPY
  • QUESTIONNAIRE MODULE
  • PROFILES REGISTRY
  • CLINICAL-PRACTICE
  • RANDOMIZED-TRIAL
  • ONCOLOGY-GROUP
  • ROGY CARE

Cite this